Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
100 hedge funds and large institutions have $142M invested in Sciclone Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 46 reducing their positions, and 12 closing their positions.
181% more call options, than puts
Call options by funds: $163K | Put options by funds: $58K
4% less capital invested
Capital invested by funds: $148M → $142M (-$5.74M)
2% less funds holding
Funds holding: 102 → 100 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
39% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.83M |
| 2 |
Millennium Management
New York
|
+$1.68M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.36M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$569K |
| 5 |
Norges Bank
Oslo,
Norway
|
+$520K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$4.85M |
| 2 |
Renaissance Technologies
New York
|
-$1.31M |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
-$1.3M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$979K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$656K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AL
101
AJO LP
Philadelphia,
Pennsylvania
| – | -$4.85M | -956,000 | Closed |
|
|
GC
102
Globeflex Capital
San Diego,
California
| – | -$1.3M | -256,278 | Closed |
|
|
I2I
103
Insight 2811 Inc
Chicago,
Illinois
| – | -$304K | -60,000 | Closed |
|
104
Fidelity International
Hamilton,
Bermuda
| – | -$206K | -40,578 | Closed |
|
|
SIM
105
Spark Investment Management
New York
| – | -$181K | -35,800 | Closed |
|
|
SCA
106
SAC Capital Advisors
Stamford,
Connecticut
| – | -$115K | -22,664 | Closed |
|
|
NCCM
107
Nine Chapters Capital Management
Short Hills,
New Jersey
| – | -$52K | -10,300 | Closed |
|
108
Schroder Investment Management Group
London,
United Kingdom
| – | -$18.8K | -3,700 | Closed |
|
109
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$12K | -2,374 | Closed |
|
110
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$5K | -1,000 | Closed |
|
SCLN Hedge Fund Activity: Q4 2013 in Review
100 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2013, worth a combined $142M — down 3.9% from $148M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of SCLN and 10 opened new positions — a net loss of 2 holders — while 46 trimmed existing stakes and 28 added.
The largest buyer was Nantahala Capital Management, adding an estimated $2.83M. The largest seller was AJO LP, exiting entirely with an estimated $4.85M sold.
- 100 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2013, down from 102 in Q3 2013.
- Funds reported $142M of Sciclone Pharmaceuticals Inc stock for Q4 2013, down 3.9% quarter-over-quarter.
- 10 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2013 and 12 closed out, a net change of -2 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q4 2013 was Nantahala Capital Management, an estimated $2.83M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q4 2013 was AJO LP, an estimated $4.85M sold.
Based on aggregated 13F filings for Q4 2013.